HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome.

Abstract
A double-blind crossover trial of the alpha 2 agonist lidamidine hydrochloride in 72 patients with irritable bowel syndrome is reported. Lidamidine was found to have no significant effect on frequency and severity of abdominal pain or abdominal bloating. It did cause a statistically significant reduction in frequency of defaecation (P = 0.005), but this was of a degree unlikely to be of clinical importance. Although alpha 2 agonists inhibit gastrointestinal motility in animals this study suggests that lidamidine hydrochloride does not have a useful therapeutic role in irritable bowel syndrome.
AuthorsA Prior, K M Wilson, P J Whorwell
JournalAlimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 2 Issue 6 Pg. 535-9 (Dec 1988) ISSN: 0269-2813 [Print] England
PMID2908757 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic alpha-Agonists
  • Phenylurea Compounds
  • lidamidine
Topics
  • Adolescent
  • Adrenergic alpha-Agonists (therapeutic use)
  • Adult
  • Colonic Diseases, Functional (drug therapy)
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Phenylurea Compounds (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: